# DTx Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dtx-pharma

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.dtxpharma.com
- Total disclosed funding: $115M
- Latest round: Series B (Feb 26, 2021)
- Investors on record: 12

## About

Based in California, US, and founded in 2017, DTx Pharma, Inc. operates as a biotechnology company that develops RNA-based therapeutics to treat genetic drivers of diseases. The company was founded by Arthur Suckow, John Grund, and Adam Pavlicek. In July 2023, Novartis acquired DTx Pharma, Inc. for USD 500 million, including an additional USD 500 million on achievement of pre-specified milestones. 

The company provides a FALCON platform (Fatty Acid Ligand Conjugated OligoNucleotide) that enables the delivery of RNA therapeutics for neuromuscular diseases.

Following the acquisition, Novartis aims to advance the development of DTx Pharma, Inc.'s CMT1A therapeutic program and the FALCON platform.

## Funding rounds

- Series B, Feb 26, 2021, $100M — Access Industries, RA Capital Management, Cormorant Asset Management, Exsight ventures, Janus Henderson Investors, Surveyor Capital, Friedman Bioventures, Logos Capital, Lilly, Viva BioInnovator
- Series A, Sep 20, 2019, $12M — Tech Coast Angels, Exsight ventures, Friedman Bioventures, Viva Biotech Holdings, Lilly
- Series A, May 14, 2019, $3M — Tech Coast Angels, Friedman Bioventures

## Investors

- Tech Coast Angels — Series A
- Friedman Bioventures (https://capitalatlas.ai/funds/friedman-bioventures) — Series A, Series B
- Exsight ventures (https://capitalatlas.ai/funds/exsight-ventures) — Series A, Series B
- Viva Biotech Holdings — Series A
- Lilly — Series A, Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Janus Henderson Investors — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series B